chemotherapy Dose, frequency and no.of cycles Adverse events
Cisplatin (P) (Every 3 weeks, RT days 1, 22, 43) P: 100 mg/m2 on day 1 (Grade 3–5 increased frequencies, compared with control arm, occurring in more than 10% of patients) Nausea/vomiting (12–40%) Neutropenia (13%) Infection (12%) Peripheral neuropathy (10%) Nausea/vomiting (12–40%) Neutropenia (13%) Infection (12%) Peripheral neuropathy (10%)
Cetuximab Loading dose: 400 mg/m2 (4–10 days prior to RT) Maintenance: 250 mg/m2 weekly during RT) (Grade 3–5 increased frequencies) Infusion reactions (3%) Acneiform rash (17%) Hypomagnesemia
TPF (TAX 324) Docetaxel (T) Cisplatin (P) 5-FU (F) (Every 3 weeks for 3 cycles) T: 75 mg/m2 on day 1 P: 100 mg/m2 on day 1 F: 1000 mg/m2 CI days 1–4 (Grade 3 or 4 frequencies) Neutropenia (33%) Infection (7%) Febrile neutropenia (5%)
TPF (European) Docetaxel (T) Cisplatin (P) 5-FU (F) (Every 3 weeks for 4 cycles) T: 75 mg/m2 on day 1 P: 75 mg/m2 on day 1 F: 750 mg/m2 by CI days 1–5 (Grade 3 or 4 frequencies) Neutropenia (77%) Alopecia (12%) Infection (7%) Febrile neutropenia (5%)
Cisplatin (P) 5-FU (F) P: 100 mg/m2 on day 1 F: 1000 mg/m2 by CI days 1–5 Nausea/vomiting (7–14%) Hematologic (52–56%) Infection (5–6%) Peripheral neuropathy (1–4%)